Four or more biopsies proffer little additional benefit, found a study presented at the IASLC 19th World Conference on Lung Cancer.
In recent years, advances in the molecular analysis of tumors and pathologic investigation have improved understanding of an ambit of lung cancer types.
A new proteomic analysis found that CT45 is an independent prognostic factor in patients with high-grade serous ovarian cancer, and a potential target of immunotherapies.
New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.
A study shows TRK gene fusions in hematologic cancers may respond to larotrectinib.
Nanotechnological strategies are making preclinical strides toward more effective, less toxic, immunotherapies.
Two presentations at the IASLC WCLC 2018 discussed the evidence on treating breathlessness with pharmacologic vs nonpharmacologic therapy.
Pembrolizumab plus chemotherapy failed to improve survival compared with pembrolizumab alone in patients with non–small-cell lung cancer.
A study shows hyperprogressive disease (HPD) occurred more commonly among patients with pretreated non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors.
The study confirmed a significant effect of male sex on PTC-specific patient survival in individuals with the most frequent oncogenic mutation.